Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the extension of its C-Scrub antimicrobial wash brand into the veterinary and animal health sector through the planned launch of a veterinary formulation of C-Scrub Wash 4%, marking the Company's first entry into the animal health market.

The Company intends to launch the veterinary formulation in the United Kingdom, where C-Scrub is already an established and commercially active human-use brand, with broader international expansion to follow.

The global animal health market was estimated at approximately $68.7 billion in 2025 and is projected to reach $156.0 billion by 2033, growing at a compound annual growth rate of 11.0%, according to Grand View Research.

Brand Extension into Animal Health

C-Scrub Wash 4%, manufactured by the Company's wholly owned subsidiary Cana Laboratories S.A., is a commercially available human-use antimicrobial skin cleanser.

The Company is now extending the C-Scrub brand into the veterinary space following successful independent testing of C-Scrub Wash 4% according to European veterinary disinfectant standards.

This extension leverages the existing product, manufacturing infrastructure, and brand equity of C-Scrub to address a distinct and rapidly growing segment within animal healthcare.

European Veterinary Standards Testing

C-Scrub Wash 4% successfully demonstrated bactericidal activity according to EN 1656:2019 and yeasticidal activity according to EN 1657:2024 following independent testing conducted by Quality Assurance & Control Systems Ltd. (QACS), an EU-based testing laboratory accredited according to EN ISO/IEC 17025:2017. Testing was conducted in May 2026 under clean conditions (3g/L bovine albumin) at 20°C with a 10-minute contact time.

Under EN 1656:2019, C-Scrub Wash 4% demonstrated bactericidal activity meeting the required ≥5 log reduction criterion against four reference organisms required under EN 1656 testing — Pseudomonas aeruginosa, Staphylococcus aureus, Proteus hauseri, and Enterococcus hirae — at both undiluted (80%) and 50% concentrations.

Under EN 1657:2024, the product demonstrated yeasticidal activity meeting the required ≥4 log reduction criterion against Candida albicans at both undiluted (80%) and 50% concentrations.